- Home
- AEMD vs HSCS Comparison
AEMD vs HSCS Comparison
Compare AEMD & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- HSCS
- Stock Information
- Founded
- AEMD 1984
- HSCS 2007
- Country
- AEMD United States
- HSCS United States
- Employees
- AEMD N/A
- HSCS N/A
- Industry
- AEMD Medical/Dental Instruments
- HSCS Medical Specialities
- Sector
- AEMD Health Care
- HSCS Health Care
- Exchange
- AEMD Nasdaq
- HSCS Nasdaq
- Market Cap
- AEMD 4.1M
- HSCS 3.7M
- IPO Year
- AEMD N/A
- HSCS 2022
- Fundamental
- Price
- AEMD $1.14
- HSCS $3.38
- Analyst Decision
- AEMD Buy
- HSCS Strong Buy
- Analyst Count
- AEMD 2
- HSCS 2
- Target Price
- AEMD $28.75
- HSCS $13.00
- AVG Volume (30 Days)
- AEMD 126.6K
- HSCS 139.1K
- Earning Date
- AEMD 08-13-2025
- HSCS 09-11-2025
- Dividend Yield
- AEMD N/A
- HSCS N/A
- EPS Growth
- AEMD N/A
- HSCS N/A
- EPS
- AEMD N/A
- HSCS N/A
- Revenue
- AEMD N/A
- HSCS $4,350.00
- Revenue This Year
- AEMD N/A
- HSCS $21,003.45
- Revenue Next Year
- AEMD N/A
- HSCS $533.33
- P/E Ratio
- AEMD N/A
- HSCS N/A
- Revenue Growth
- AEMD N/A
- HSCS N/A
- 52 Week Low
- AEMD $1.09
- HSCS $2.36
- 52 Week High
- AEMD $8.44
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- AEMD 38.81
- HSCS 44.73
- Support Level
- AEMD $1.09
- HSCS $3.33
- Resistance Level
- AEMD $1.41
- HSCS $3.82
- Average True Range (ATR)
- AEMD 0.09
- HSCS 0.32
- MACD
- AEMD 0.02
- HSCS 0.00
- Stochastic Oscillator
- AEMD 15.62
- HSCS 52.69
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.